Infertility risk and teratogenicity of molecularly targeted anticancer therapy: A challenging issue

Research output: Contribution to journalArticle

Abstract

The growing population of young cancer survivors and a trend toward postponing pregnancy until later in life are shifting areas of focus toward understanding treatment induced sequelae, particularly the effects of cancer and/or treatment on fertility. Whereas the fertility risk of cytotoxic agents for both men and women is well-recognized, the fertility risks and teratogenic potential associated with molecular targeted therapies are not established. We summarize available preclinical and clinical data on the impact of new molecular targeted agents on fertility in both sexes, and their potential teratogenic effects, providing recommendations for clinicians, where possible. Agents were categorized by class and the potential relevance of their target signaling pathways to gonadal maturation discussed.

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalCritical Reviews in Oncology/Hematology
Volume107
DOIs
Publication statusPublished - Nov 2016

Fingerprint

Infertility
Fertility
Fertility Agents
Molecular Targeted Therapy
Cytotoxins
Survivors
Neoplasms
Therapeutics
Pregnancy
Population

Keywords

  • Review
  • Journal Article

Cite this

@article{47811e85a37c482db1b74015a591d176,
title = "Infertility risk and teratogenicity of molecularly targeted anticancer therapy: A challenging issue",
abstract = "The growing population of young cancer survivors and a trend toward postponing pregnancy until later in life are shifting areas of focus toward understanding treatment induced sequelae, particularly the effects of cancer and/or treatment on fertility. Whereas the fertility risk of cytotoxic agents for both men and women is well-recognized, the fertility risks and teratogenic potential associated with molecular targeted therapies are not established. We summarize available preclinical and clinical data on the impact of new molecular targeted agents on fertility in both sexes, and their potential teratogenic effects, providing recommendations for clinicians, where possible. Agents were categorized by class and the potential relevance of their target signaling pathways to gonadal maturation discussed.",
keywords = "Review, Journal Article",
author = "E. Lorenzi and Matteo Simonelli and Armando Santoro",
note = "Copyright {\circledC} 2016 Elsevier Ireland Ltd. All rights reserved.",
year = "2016",
month = "11",
doi = "10.1016/j.critrevonc.2016.08.005",
language = "English",
volume = "107",
pages = "1--13",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Infertility risk and teratogenicity of molecularly targeted anticancer therapy

T2 - A challenging issue

AU - Lorenzi, E.

AU - Simonelli, Matteo

AU - Santoro, Armando

N1 - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

PY - 2016/11

Y1 - 2016/11

N2 - The growing population of young cancer survivors and a trend toward postponing pregnancy until later in life are shifting areas of focus toward understanding treatment induced sequelae, particularly the effects of cancer and/or treatment on fertility. Whereas the fertility risk of cytotoxic agents for both men and women is well-recognized, the fertility risks and teratogenic potential associated with molecular targeted therapies are not established. We summarize available preclinical and clinical data on the impact of new molecular targeted agents on fertility in both sexes, and their potential teratogenic effects, providing recommendations for clinicians, where possible. Agents were categorized by class and the potential relevance of their target signaling pathways to gonadal maturation discussed.

AB - The growing population of young cancer survivors and a trend toward postponing pregnancy until later in life are shifting areas of focus toward understanding treatment induced sequelae, particularly the effects of cancer and/or treatment on fertility. Whereas the fertility risk of cytotoxic agents for both men and women is well-recognized, the fertility risks and teratogenic potential associated with molecular targeted therapies are not established. We summarize available preclinical and clinical data on the impact of new molecular targeted agents on fertility in both sexes, and their potential teratogenic effects, providing recommendations for clinicians, where possible. Agents were categorized by class and the potential relevance of their target signaling pathways to gonadal maturation discussed.

KW - Review

KW - Journal Article

U2 - 10.1016/j.critrevonc.2016.08.005

DO - 10.1016/j.critrevonc.2016.08.005

M3 - Article

C2 - 27823636

VL - 107

SP - 1

EP - 13

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -